Curriculum Vitae

Curriculum Vitae



Ritchie C. Shoemaker, M.D.

DOB:  06-13-51 Charlotte N.C. US Citizen

Home address:  2448 Lakeland Drive, Pocomoke, Maryland 21851


Current Employment

Ritchie C. Shoemaker MD. PA. DBA Chronic Fatigue Center, retired 1/27/2013

Ritchie C. Shoemaker MD PA

Medical Director, Center for Research on Biotoxin Associated Illnesses (501-c-3, non-profit.)

Medical Director,

Medical Director ProgeneDx.


College: Duke University 1969-1973 Magna Cum Laude

   Major in Molecular Biology, Zoology. Minor in Philosophy.



  • Microtubule control of phototactic responses in Euglena, 1971.
  • Localization of DNA replication sites in Tetrahymena by electron microscopy, autoradiography and tritiated thymidine counts, 1972.


Medical School:  Duke University 1973-77

Editor – “First Contact” Medical Student Primary Care Journal


  • Molecular basis for muscle injury and repair 1974
  • Ventilation-perfusion abnormalities in chronic lung disease 1975
  • Epidemiology of streptococci 1976


Residency 1977-80

   Family Practice Residency, Williamsport Hospital, 777 Rural Ave, Williamsport, PA 17013


Board Certification ABFP 1980; recertification through 2006

MD License 1980 to present. D24924


Professional Memberships

  • AMA 2001-2011
  • ACSM 1977-1996
  • American Society of Bariatric Physicians 1998-2001
  • American Academy of Family Physicians 1999-2001
  • American Society for Microbiology 1999-2013
  • American College of Occupational and Environmental Medicine 2/6/05-2/6/06
  • American Society of Tropical Medicine and Hygiene 11/05-11/08
  • American Industrial Hygiene Association 2008-2010
  • International Society on Indoor Air Quality 6/10-6/2011
  • International Association for Chronic Fatigue Syndrome 4/05-5/2012
  • Maryland Medical Chirurgical Association (Med Chi) 1980-present; emeritus 2013
  • Maryland Academy of Family Physicians 1999-2001



Practice Experience

  • 7/1980-9/1982 NHSC Pocomoke, Maryland. 
  • 10/1982 to present, Private Practice, Pocomoke, Maryland

               Outpatient Family Medicine

               1604 Market St 10/1982-5/2002

               Biotoxin Illnesses

               500 Market Street, Suites 102,103 5/2002-1/27/2013 

                              Pocomoke City, Maryland 21851

               Retired from clinical practice 1/27/2013

               Medical Director ProgeneDx 1/1/2016-present

               Medical Director Surviving Mold 1/1/2010-present


Teaching Appointments

  • Milton Hershey Medical School 1980-90, Physician Assistant Preceptor;
  • Johns Hopkins Medical School 1981-86;
  • Duke University Medical School 1983-85;
  • Wilmington College Nurse Practitioner Program 1996-1997;
  • University of Maryland Medical School 1997-present.

   NB:  These appointments are for community preceptorships only and are not salaried


Hospital Affiliation, Active Staff, McCready Hospital, Crisfield, Maryland 1980-1986; 1997-6/2003, courtesy

   1986-1997; and 7/2003-1/28/2013, pure outpatient practice (no demands ever to reduce privileges).


George Washington University Clinical Faculty (community) 2014-present


Medical Society

  • President, Somerset County 1982-86
  • Member, Worcester County 1986-1997
  • President, Somerset County 1998-2005


Credentialed By

  • Medicare, Medicaid, BCBS, MDIPA, DHP, Alliance, Prudential, Principal, Aetna American Health Care, Infor Med, PHCS, Trigon, many others.
  • Never denied credentials  


Additional work experience

Shoemaker’s Bench, Antique Refinishing and Restoration 1966-present.  Historic Remodelers of the Eastern Shore 1981-1986. Wetland Consultant 1983-present. Visiting Medical Lecturer 1991-present.


Website 12/10-present


 Books published

  • Pandora Boxer 1976
  • Hematology for Residents 1978 (out of print)
  • Weight Loss:  Stay Off the Amylose 1984
  • Weight Loss and Maintenance; My Way Works?
    • First printing 1996; Second printing 1998.
  • Pfiesteria: Crossing Dark Water
    • First printing 1997; Second printing 1998
  • Desperation Medicine
    • 1/15/01 Second printing 6/06 Third printing 6/2008
  • Lose the Weight You Hate
    • First printing 2/02; Second printing 10/05
  • Mold Warriors 4/05; second printing 12/2007
  • Discovery Nature Trail, Pocomoke City Maryland:  A Guide for Walkers 2009
  • Surviving Mold:  Life in the Era of Dangerous Buildings 12/2010
  • State of the Art Answers to 500 Mold Questions; ebook 7/1/2014
  • A Gene Primer for Health Care Providers  The Genomics of CIRS and Associated Molecular Pathways: Interpreting the Results 2/2018
  • STATE OF THE ART Mold Answers 501-800 2019
  • The Art and Science of CIRS Medicine; Shoemaker R, McMahon S, Heyman A. 2021


Columnist Worcester County Messenger weekly newspaper; “What’s Cooking” 1994-2001


Editorials Published

   Daily Times of Salisbury (many), Maryland Environmental Health Newsletter,

   Outlook (op-ed) Washington Post, Baltimore Sun, Multiple Florida Newspapers,

   Runoff Magazine, CCA Journal, Feature article with Duke Alumni Magazine (twice),

   Family Practice News, Internal Medicine News, OB-GYN News, Delmarva Farmer (many), Asbury (NJ) Press



National television appearances

Good Morning America, BBC, Australian Broadcasting System, NBC News, CBS News, Discovery Health Channel: “Dangerous Catch” and “Is Your House out to Get You;” CNN, ABC News; Discovery Health Channel Planet Green; filmed three pilots 12/08 on (i) red tide; (ii) ciguatera; (iii) water-damaged buildings for Mystery Environmental Illness.  Discovery Health Channel, Planet Green, Toxic Files, 12/12/09.  Aspergillus can kill you; Oprah Winfrey Network 1/11. Monsters inside us (Animal Planet, 2015).


Script consultant: 9/15 CSI: Cyber episode 104


Local TV station appearances

Multiple: Salisbury, Md., Washington, DC, Baltimore, Md, Stuart, Florida, Philadelphia, Pa, Leesburg, Florida, New Orleans, Louisiana



  • “The Death of Edgar Allen Poe” What Really Happened MMJ 4/97
  • Diagnosis of Pfiesteria Human Illness Syndrome, Maryland Medical Journal 1997; 46(10): 521-3.
  • Treatment of Persistent Pfiesteria Human Illness Syndrome, MMJ 1998; 47(7): 64-66.
  • Co-author, Grattan et al, Lancet 1998; 352: 532-41.  Learning and memory difficulties after environmental exposure to waters containing Pfiesteria or pfiesteria-like dinoflagellates.
  • Hippocrates 2000; February, Viewpoint Housecall: A crisis in the air restores a physician’s faith in medicine
  • Possible Estuary-Associated Syndrome, Environmental Health Perspectives 2001; 109(5): 539-545. Grand Rounds in Environmental Medicine   
  • Residential and Recreational Acquisition of Possible Estuarine Associated Syndrome:  A New approach to Successful Diagnosis and Therapy, Environmental Health Perspectives, Special CDC Pfiesteria Supplement, 2001; 109S5; 791-796. 
  • How Sick is Your Building and What You can do About it, Filtration News, June, 2001
  • Getting Inside Sick Building Syndrome, Filtration News, July, 2001
  • American Diabetes Association, Diabetes 2002; 51(2) Supplement: A133.  Use of pioglitazone to prevent intensification of persistent symptoms following cholestyramine treatment of patients with Post-Lyme syndrome
  • A Primer in Sick Building Syndrome:  Lessons from the Somerset County District Court, Filtration News June, 2002
  • Lyme Times 2002; 33: 13-16.  Lyme, an Infectious Disease and a Neurotoxin Illness.
  • Lyme Times 2002; 33: 38-40. Someone Has to Tell; a patient’s story.
  • Environmental Health Perspectives 2002; 110: A121-A123, letter.  Visual contrast sensitivity, response.
  • Environmental Health Perspectives 2003; 111(1): A18-19, letter.  Neuropsychologic Testing versus Visual Contrast Sensitivity:  Response..
  • 9/2004. As I see it. Pythagoras and the Atlantic white cedar.
  • 9/2004. The Biotoxin Pathway.
  • Medical Conditions Arising from Environmental Conditions, interview, Filtration News, July 2003
  • Moldy buildings:  It’s a jungle in there.  Filtration News, Nov 2004
  • Neurotoxicology and Teratology, January 2005.  R. Shoemaker and D. House, A time-series of sick building syndrome; chronic, biotoxin-associated illness from exposure to water-damaged buildings. Neurotoxicology and Teratology 2005; 27(1) 29-46.
  • Sick Building Syndrome in water-damaged buildings: Generalization of the chronic biotoxin-associated illness paradigm to indoor toxigenic fungi; 5/2005; Pg 66-77 in Johanning E. Editor, Bioaerosols, Fungi. Bacteria, Mycotoxins and Human Health. R Shoemaker, JM Rash, EW Simon.
  • To Build a Safe House, Filtration News, June 2005
  • Defining Sick Building Syndrome in adults and children in a case-control series as a biotoxin-associated illness:  diagnosis, treatment and disorders of innate immune response, MSH, split products of complement. IL-1B, IL-10, MMP9, VEGF, autoimmunity and HLA DR; American Society of Tropical Medicine and Hygiene; 12/14/05
  • C3a and C4a:  complement split products identify patients with acute Lyme disease; ASTMH, 12/4/05
  • MMP9, visual contrast sensitivity, C3a, C4a and HLA DR: New diagnostic aids in acute and chronic Lyme disease, ASTMH, 12/14/05
  • Atovaquone plus cholestyramine in patients co-infected with Babesia microti and Borrelia burgdorferi refractory to other treatment, Advances in Therapy 2006; 23(1): 1-11.  Shoemaker RC, Hudnell KH, House DE, van Kempen A, Pakes GE for the COL 40155 Study Team.
  • American Society for Microbiology Biodefense Research meeting 2/16/06 Hyperacute physiological changes following prospective exposures to environmental sources of trichothecene toxins in water-damaged buildings (WDB): A Stealth toxin is revealed.
  • SBS and exposure to water damaged buildings:  time series study, clinical trial and mechanisms; Neurotoxicology and Teratology 2006; 28: 573-588.  R Shoemaker, D House.
  • Mold Illness after Katrina:  The truth you haven’t heard.  Filtration News, May, June 2006
  • AAAAI; rebuttal to Bush position paper, endorsed by 125 PhDs and MDs; JACI 2006; 118: 764-766.  Co-authors: Harriett Ammann PhD; Richard Lipsey PhD; and Ed Montz PhD.
  • ASTM International, Section D22, Boulder Colorado 7/27/06.  Bringing science to bear on moisture and mold in the built environment.  “Defining causality of a biotoxin-associated illness by exposure to water-damaged buildings:  a case control series.”
  • ASTMH 11/06 Defining chronic ciguatera illness by abnormalities in innate immune responses: final common pathways of biotoxin-associated illnesses.
  • ASTMH 11/06 Eight-year follow-up of patients with Possible Estuarine Associated Syndrome (PEAS): symptom reduction didn’t result in cure.
  • International Association for Chronic Fatigue Syndrome 1/14/07.  Treatment of elevated C4a in patients with CFS using low doses of erythropoietin safely reduces symptoms and lowers C4a:  a prospective clinical trial.
  • International Association for Chronic Fatigue Syndrome 1/14/07.  Treatment of CFS patients with elevated C4a using low dose erythropoietin corrects abnormalities in central nervous system metabolites and restores executive cognitive functioning.
  • International Association for Chronic Fatigue Syndrome 1/14/07.  Treatment of CFS patients with low levels of vasoactive intestinal polypeptide (VIP) and shortness of breath with tadalafil improves exercise tolerance and pulmonary artery pressure responses to exercise.
  • Inside Indoor air quality 4/15/07, with King-teh Lin PhD.  Filtration News May/June 2007.
  • Sonoma CFS symposium 8/12-16/07.  Shoemaker for dummies.
  • 10/3/07 Allergy Clin Immunol Int: J World Allergy Org 2007 Supplement 2.  C3a and C4a:  Complement split products identify patients with hyperacute Lyme disease.
  • 10/14/07 IAQA, Las Vegas, Nevada. Sequential activation of innate immune elements:  a health index for people re-exposed to water-damaged buildings.
  • ASTMH 11/07.  Correction of central nervous system metabolic abnormalities, deficits in executive cognitive functioning and elevated C4a:  a clinical trial using low dose erythropoietin in patients sickened by exposure to water-damaged buildings.
  • ASTMH 11/07.  Sequential upregulation of innate immune responses during acute acquisition of illness

in patients exposed prospectively to water-damaged buildings; with scoring rubric.

  • ASTMH 11/07.  Defining mold illness in children:  a chronic inflammatory illness with distinctive biomarkers.
  • International Archives of Allergy and Immunology, 2008; 146: 255-261.  C3a and C4a define acute Lyme disease.  Shoemaker RC, Giclas P, Glovsky M.
  • Indoor Environmental Communications 1/08.  Shoemaker RC and Lin, Kin-teh.  The ever-expanding database on pathophysiology of illness caused by exposure to water-damaged buildings.
  • Characterization of chronic human illness associated with exposure to cyanobacterial harmful algal blooms predominated by Microcystis.  Shoemaker RC and House D, in Cyanobacterial Harmful Algal Blooms: State of the Science and Research Needs, edited by HK Hudnell, US EPA; ISOC HAB.  Advances in Experimental Medicine and Biology, volume 619, 2/08.
  • AIHA 6/08 Shoemaker R.  When SAIIE meets ERMI:  correlation of indices of human health and building indices.  Minneapolis, Minnesota.
  • Sonoma CFS symposium 9/24-9/28/08 Innate immune responses define pediatric illness in patients sickened by exposure to water-damaged buildings.
  • Sonoma CFS symposium 9/24-9/28/08 TGF beta-1 in treatment of autoimmunity in chronic inflammatory illness acquired following exposure to water-damaged buildings associated with HLA DR by PCR.
  • IACFS 3/09; Reno, Nevada.  Innate immune responses define pediatric CFS.
  • IACFS 3/09; Reno, Nevada.  TGF beta-1 in treatment of autoimmunity in CFS associated with HLA DR by PCR.
  • Sonoma CFS symposium; 4/22/09.  Replacement dosing of VIP restores regulatory control to dysregulated innate immune mechanisms, corrects inflammatory reactivity and eliminates symptoms of chronic fatiguing illnesses.
  • Sonoma CFS symposium.  Correction of elevated TGF beta-1 using losartan safely corrects autoimmunity.
  • AIHA 6/09. ERMI correlates with Abnormalities in Innate Immunity.  Toronto, Ontario.
  • IACFS Bulletin, Summer, 6/09.  Exposure to interior environments of water-damaged buildings causes a CFS-like illness in pediatric patients:  a case/control study.
  • Healthy Buildings; Syracuse, NY, 9/09. Innate immunity, MR spectroscopy, HLA DR, TGF beta-1, VIP and capillary hypoperfusion define acute and chronic human illness acquired following exposure to water-damaged buildings.
  • 11/16/09 Fifth Symposium on Harmful Algae in the US.  Ocean Shores, Washington.  Using markers of chronic systemic inflammatory disturbances to define chronic ciguatera as a biotoxin illness:  a case/control study.
  • 5/28/10 First ME/CFS Conference, Copenhagen, Denmark.  European Society for ME.  The academic basis for the treatment of ME/CFS in 2010.  Keynote speaker.
  • 6/4/10 Defining the neurotoxin derived illness chronic ciguatera using markers of chronic systemic inflammatory disturbances: A case/control study.  Neurotoxicology and Teratology 2010 doi: 10.1016/  6/4/10.  R Shoemaker, D House, J Ryan.
  • 7/27/10 Shoemaker R, Mark L, McMahon S, Thrasher J, Grimes C.  Policyholders of America.  Research Committee Report on diagnosis and treatment of chronic inflammatory response syndrome caused by exposure to the interior environment of water-damaged buildings.
  • 8/1/10 9Th International Mycology Congress, Edinburgh, Scotland.  Exposure to water-damaged buildings causes a readily identifiable chronic inflammatory response syndrome that is successfully treated by a sequential intervention protocol.
  • 1/12/11 Keystone symposia (invited lecture).  TGF beta-1 in Human Health, Salt Lake City, Utah
  • 1/30/11 Lyme Roundtable (keynote), Virginia Beach.  Inflammatory basis for Post-Lyme Syndrome
  • 9/6/2011-9/9-2011 6th International Scientific Conference on Bioaerosols, Fungi, Bacteria, Mycotoxins in Indoor and Outdoor Environments and Human Health, Saratoga Springs, NY
  • Vasoactive Intestinal Polypeptide (VIP): a final step in correction of the inflammatory illness acquired following exposure to water-damaged buildings
  • T regulatory cells in chronic inflammatory response syndrome from water-damaged buildings (CIRS-WDB)
  • HERTSMI-2 Simplifying analysis of safety of WDB
  • 1/26/2012 Physician Round Table, Tampa, Florida. Proteogenomics of Lyme Disease.
  • 3/12/2013 Shoemaker RC, House D, Ryan JC. Health 2013; 5(3): 396-401. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings.
  • 10/21/2013 Biotoxin Illness: the science behind accurate diagnosis and effective treatment, San Luis Obispo, California
  • 10/21/2013 NeuroQuant: New diagnostic test holds great promise. San Luis Obispo, California.
  • 3/1/14 Post Lyme as a Chronic Inflammatory Response Syndrome; Round Table, Tampa, Florida
  • 6/2013 CRBAI: Research Guidelines. Shoemaker R, Hudnell K.
  • 4/6/2014. As I see it. ERMI and the EPA
  • 6/5/2014 Shoemaker RC, House, D, Ryan JR.  Neurotoxicology and Teratology doi: 10.1016/ Structural brain abnormalities in patients with inflammatory illness acquired following exposure to water-damaged buildings: A volumetric MRI study using NeuroQuant.
  • 9/26/2014 Chronic Inflammatory Response Syndrome meets NeuroQuant; San Diego, California
  • 9/27/2014 Bio-Hacking a Chronic Inflammatory Response Syndrome; Second Annual BulletProof conference, Pasadena, California
  • 10/8/2014 Keynote address, CIRS as Seen as a Scientific Revolution, Salisbury, Maryland. State of the Art conference in CIRS.
  • 11/1/2014. Shoemaker R. CIRS: from anomaly to paradigm.
  • 12/18/14 Shoemaker R. As I see it. Owls under a beaver moon.
  • 4/4/2015 Transcriptomic signatures in whole blood of patients who acquire a chronic inflammatory response syndrome (CIRS) following an exposure to the marine toxin ciguatoxin.

James C Ryan, Qingzhong Wu and Ritchie C Shoemaker. BMC Medical Genomics (2015) 8:15

DOI 10.1186/s12920-015-0089-x.

4/11/2015 Shoemaker R. Norvect, Oslo, Norway. NeuroQuant, Lyme and mold. Implications for enhanced diagnostic accuracy.

  • 10/31/2015. Medically sound investigation and remediation of water-damaged buildings in cases of CIRS-WDB. Part 1. Berndtson K, McMahon S, Shoemaker R.
  • 3/31/2016 McMahon S, Shoemaker R, Ryan J. Reduction in Forebrain Parenchymal and Cortical Grey Matter Swelling across Treatment Groups in Patients with Inflammatory Illness Acquired Following Exposure to Water-Damaged Buildings. Journal of Neuroscience and Clinical Research 2016; 1: 1-4
  • 4/15/16 Shoemaker R. VO2 max: it isn’t just CFS. SM lecture
  • .4/15/16 Shoemaker R. Pulmonary hypertension
  • 11/3/16. Shoemaker R, Katz D. Response to FDA review of VIP.
  • 4/16/2016. Medically sound investigation and remediation of water-damaged Buildings in cases of CIRS-WDB. Part 2. Larry Schwartz CIEC, BSME, MBA, Greg Weatherman CMC, Michael Schrantz CIEC, CMI, Will Spates CIAQP, CIEC, Keith Berndtson MD, Ritchie Shoemaker MD
  • 7/3/2016. Shoemaker R, Lark D. HERTSMI-2 and ERMI: “Correlating Human Health Risk with Mold Specific qPCR in Water-Damaged Buildings”, #658 in Proceedings of the 14th International Conference on Indoor Air Quality and Climate, International Society for Indoor Air Quality and Climate, Ghent, Belgium
  • 10/30/2016. Ryan, J, Shoemaker R. RNA-Seq on patients with chronic inflammatory response syndrome (CIRS) treated with vasoactive intestinal polypeptide (VIP) shows a shift in metabolic state and innate immune functions that coincide with healing. Medical Research Archives. 2016; 4(7): 1-11.
  • 3/25/2017.  Shoemaker RC, Katz D, McMahon S, Ryan J. Internal Medicine Alert 2017; 3(4): 1-14. Intranasal VIP safely restores atrophic grey matter nuclei in patients with CIRS.
  • 5/17/2017. Shoemaker R, Lark D, Ryan J. Healthy Buildings Europe 2017. Exposure to buildings with elevated MSQPCR reduces health benefits from VIP treatment of CIRS-WDB
  • 6/2017. Age adjusted NeuroQuant scoring rubric.
  • 7/1/2017 Shoemaker R, Ryan J. A treating physician’s perspective on ciguatera. CRC Handbook on Foodborne Illness. Publication 2019.  Chapter 94.
  • 8/15/2017 Shoemaker R, Ryan. Musculoskeletal pain and chronic inflammatory illness.  CRC Handbook on Chronic Pain. Publication date 2019.
  • 9/7/2017. Shoemaker R, Ryan J. US PATENT 9,770,170 B2. Methods of diagnosing, treating and monitoring chronic inflammatory response syndrome.
  • 10/14/2017 Shoemaker R, Heyman A, Lancia A, Ryan J. Inflammation induced chronic fatiguing illnesses: a steady march to identifying mechanisms and identifying new biomarkers and treatment. Int Med Rev. 2017; 3 (11): 1-37.
  • 12/1/2017. Shoemaker, R. Cardiomyopathy and GENIE at five-time points Lyme:
  • 1/18. Ryan J, Shoemaker R. Chronic fatigue: a condition seen in messenger RNA Seq.
  • 5/3/2018 Shoemaker R, Johnson K, Jim L, Berry Y, Dooley M, Ryan J, McMahon S. Diagnostic Process for Chronic Inflammatory Response Syndrome (CIRS): A Consensus Statement Report of the Consensus Committee of Surviving Mold. Int Med Rev 2018; 4:1-46.
  • 9/2/2018. Shoemaker R. Proficiency partners lecture series, with sound
  • 2/23/2019. Shoemaker R. Transcriptomics the final frontier. Surviving mold.
  • 7/2/2019 Townsend Letter, 5 issue series through 12/19. Moldy buildings, sick people and damaged brains: 25 years of research brought us to the cure word.
  • 8/10/19. Shoemaker R. Actinos in WDB. CIRSX Roswell, NM
  • 10/8/19 Shoemaker R, Lark D. MRA Urinary mycotoxins: contaminated food and a misleading biomarker
  • 10/16/19. Shoemaker R.  Lessons from GENIE 1. What do the data show?
  • 11/4/2019. Shoemaker R. Ancillary studies in CIRS
  • 4/2020 Shoemaker R. NeuroQuant and GENIE
  • 4/20. SHOEMAKER R. Indoor Environmental Professional Panel of Surviving Mold CONSENSUS STATEMENT for Microbial Remediation. Internal review performed by The Professionals Panel of
  • 5/22/2020 Shoemaker R. Lessons from GENIE: WHEN DATA MATTER.
  • 5/29/20. Shoemaker R. Endotoxins and CIRS. Mold Congress
  • 6/2020. GENIE Interpretation template.
  • 9/2020. Shoemaker R. Metabolism, molecular hypometabolism and inflammation: Complications of proliferative physiology include metabolic acidosis, pulmonary hypertension, T reg cell deficiency, insulin resistance and neuronal injury. Trends Diabetes Metab 2020; 3: 1-15
  • 10/11/20 Shoemaker R. Once you learn transcriptomics, you will never look back.
  • 12/3/20. Shoemaker R. Metallic taste.
  • 18/18/20 Shoemaker R. Immunity, ribosomes, VDAC, BCL2. World Congress
  • 2/21. Heyman A, Shoemaker R Ohio State Legislature directs effort to identify what toxic burden could be studied to show adverse health effects acquired following exposure to the interior of water-damaged buildings (WDB). The CIRS Study Proposal
  • 6/21 Shoemaker R, Post Covid Syndrome, TGFBR, and GENIE. A post viral syndrome
  • 7/2021 Actino Index. Shoemaker R. Surviving Mold
  • 8/29/21 Shoemaker R. Actinos and immune injury in CIRS. Surviving Mold.
  • 3/2021 Shoemaker R, Neil V, Heyman A, van der Westhuizen M, McMahon S, Lark D. Newer Molecular Methods Bring New Insights into Human- and Building-Health Risk Assessments From Water-Damaged Buildings: Defining Exposure and Reactivity, the Two Sides of Causation of CIRS-WDB Illness. Medical Research Archives 2021; 9(3): 1-36
  • 6/2021 Shoemaker R, McMahon S, Heyman A, Lark D, van der Westhuizen M, Ryan J. Treatable metabolic and inflammatory abnormalities in Post COVID Syndrome (PCS) define the transcriptomic basis for persistent symptoms: Lessons From CIRS. Medical Review Archives 2021; 9(:1-8).
  • 10/2021 MRA, Shoemaker R, Heyman A, Lark D. Exposure to resident Actinobacteria in WDB and CIRS
  • 12/14/21 MRA Shoemaker R, Lark D. Screening for biomarkers for Actinobacteria in CIRS.
  • 1/14/22 Shoemaker, R. GENIE DATA . CIRSX.
  • 1/23/2022 Algorithms for GENIE Shoemaker R.
  • 4/22. Shoemaker R. Ribosomal basis of hsvoc in molecular hypometabolism.
  • 5/28/2022 Shoemaker R, Actino skin study
  • 8/14/22. Shoemaker R, Lark D. GENIE MEETS NEUROQUANT. CIRSX.
  • 9/22 Shoemaker R, Neil V, Heyman A, van der Westhuizen M, McMahon S, Lark D. Newer Molecular Methods Bring New Insights into Human- and Building-Health Risk Assessments From Water-Damaged Buildings: Defining Exposure and Reactivity, the Two Sides of Causation of CIRS-WDB Illness. Medical Research Archives 2021; 9(3): 1-36
  • 1/2023 Shoemaker R, Lark D, Ryan J, Vukelic A. IN Aruna, ed, CRC.  Guidelines in public health policy considerations: safe buildings are a basic human right.
  • 1/2023 Shoemaker R, Lark D, Vukelic A In ARUNA A. ed in CRC. Urinary mycotoxins: An unvalidated practice for evaluation of human health.
  • 1/2023 Shoemaker R, Vukelic A, in Aruna A, ED. in CRC. CIRS and metabolism: PROLIFERATIVE PHYSIOLOGY AND INSULIN RESISTANCE.
  • 1/2023. Shoemaker, R, and Vukelic A. In Aruna A, ed in CRC. The evolution of CIRS and the Biotoxin Pathway
  • 1/2023 Shoemaker R, Lark D, Vukelic A. In Aruna A, ed in CRC. Urinary mycotoxin testing: An unvalidated practice for evaluation of human health
  • 3/1/23. Shoemaker R, Heyman A, Lark D. MRA. Transcriptomics and brain volumetrics define the causes of cognitive impairment in patients with CIRS and support use of VIP IN TREATMENT.
  • 7/27/2003 Shoemaker R CIRSX, virtual presentation, Boulder, Colo, Actino eradication study. Shoemaker R.


Peer reviewer:

               Environmental Health Perspectives; Special CDC Pfiesteria issue, 2001; comment on fungal illness 2007

               Environmental Research; 2003, 2004

               Journal of Nutritional and Environmental Medicine 2007 (small colony variants; MARCoNS)

               Heart and Lung 2007 (Babesia as FUO)

Health Policy 2/08.  The relationship between sick building syndrome and perceived indoor environmental quality in apartment buildings


Policyholders of America consensus statement of mold treating physicians: lead author, with research committee of Action Committee on Health Effects, Mold, Microbes and Indoor Contaminants. 6/14/10. 22 peer reviewers internally            


Graduate degree examiner

University on Newcastle, Australia 10/04.  Delta hemolysins production of long-term Staphylococcus epidermidis cultures. Hai Lin, Environmental and Life Sciences.



  • 4/10/00 Regional Meeting American Society of Microbiology, Lewes, Delaware.

A new approach to diagnosis and treatment of chronic Lyme disease: vision, cytokines, and cholestyramine.

  • 5/10/00- Chico, Calif.  Lyme disease as a Neurotoxin and Cytokine-Mediated Illness
  • 9/21/00 Lewes, Delaware.   Center for the Inland Bays “Pfiesteria Human Illness Syndrome and Blue Green Algae Syndrome: Emerging Estuarine Health Threats”
  • 9/24-25/00 Tallahassee, Florida.  Florida Department of Environmental Protection   Diagnosis and Treatment of a chronic neurotoxin-mediated illness from an unknown microbe at the Casteen Roads.
  • 11/4/00, Princeton, New Jersey. Annual Scientific Conference of the Lyme Disease Association Hypoperfusion of retina and neural rim of optic nerve head as biomarker for the chronic neurotoxin-mediated illness of Lyme disease.   
  • 10/25/00 American Psychiatric Association, Annual Meeting, Philadelphia, PA. Environmental Acquisition of Psychiatric Illness
  • 10/30/00 Annual Meeting of American Society of Tropical Medicine and Hygiene, Houston, Texas.

A new approach to diagnosis of chronic ciguatera illness and successful treatment with cholestyramine

  • 6/01/01 Delaware Medical Society, Lewes, Delaware.  Approach to Diseases Caused by Neurotoxins
  • 11/09/01 Lyme Disease Association, Princeton, NJ. Acute Lyme Disease
  • 11/10/01 ILADS. Princeton, NJ, Co-infection with apicomplexans and Lyme, role of extrachromosomal plastid DNA and persistent symptoms
  • 11/30/01 International Society of Neurobiology, Seattle, Washington. Neurotoxins and solutions to questions raised by chronic fatiguing illnesses
  • 2/14/02 American Academy of Environmental Medicine, St. Louis, Missouri, an 8-hour tutorial. Challenges to Clinical Paradigms:  Cytokines, neurotoxins and vision
  • 6/24/02 8th International Symposium of Neurotoxicology, Brescia, Italy. Co-Chair (with Ken Hudnell, Ph.D.) of Biotoxin Session.  Three lectures:  Sick Building Syndrome:  Possible Association with Exposure to Mycotoxins from Indoor Air Fungi (to date, the largest study on SBS in the world’s literature, 103 patients and 43 buildings); Use of pioglitazone or Omega-3s to prevent intensification of persistent symptoms following cholestyramine treatments of patients with Post-Lyme Syndrome: the multisite trial.  Metallic Taste, a marker of neurotoxicity.
  • 9/17/02 Environmental and Occupational Health Sciences Institute, Occupational Medicine Residency Program, Robert Wood Johnson Medical School, Piscataway, NJ; Neurotoxin mediated illnesses: A new approach to medically unexplained symptoms.
  • 9/20/02   International College of Integrative Medicine, Grand Rapids, Michigan. Neurotoxins, hypothalamic hormones and chronic fatiguing illnesses
  • 11/15/02 ASTMH Denver, Colo, Use of atovaquone and cholestyramine in patients co-infected with Borrelia burgdorferi and Babesia microti, refractory to all antibiotic regimens (GlaxoSmithKline funded research).
  • 12/6/02 Faculty member, National panel, Wayne State University, Michigan.  Interim clinical guidelines for the diagnosis and treatment of mold associated medical disorders; presented, “A new paradigm for diagnosis and treatment of Sick Building Syndrome, a biotoxin associated illness.”
  • 2/20/03 Univ Connecticut, Pathobiology seminar, “Biotoxins, vision, inflammatory cytokines and hypothalamic hormones in primary care medicine:  From Post-Lyme Syndrome to Sick Building Syndrome, a new paradigm for medically uncertain symptoms.
  • 7/11/03 Harris Chain of Lakes Restoration Commission, Lake County, Florida. St. John’s River Water Management District, invited lecture:  Human health effects following exposure to toxigenic cyanobacteria:  diagnosis, treatment and environmental implications   
  • 9/10/03 5th International Conference on Bioaerosols, Fungi, Bacteria, Mycotoxins and Human Health, Saratoga Springs, NY (peer reviewed). Sick building syndrome in water damaged buildings: Generalization of the chronic biotoxin associated illness paradigm to indoor toxigenic fungi (156 patients in 150 buildings).
  • 9/25/03 13th annual Environmental Information Association. Myrtle Beach, SC, keynote.  The clear link between mold exposure and human health:  What you need to know.
  • 10/30/03 Mold 5 National Institute of Building Sciences. Building envelope and thermal environment committee, San Diego, Cal, keynote, Human health effects from exposure to toxigenic fungi:  The proof of causation is here. 
  • 11/25/03 Crossing boundaries:  Medical Biodefense and Civilian/Military Medicine; First International conference, sponsored by George Mason University, National Center for Biodefense and Georgetown University, Arlington, Va.  Diagnosis and Treatment of Biotoxin Associated Illnesses:  Learning for the future from Today’s Example
  • 12/02/03 Special Report to the Federal Research Committee on Gulf War Illness.  Gulf War Illness as a Biotoxin Illness:  Report of a cohort of exposed veterans.
  • 1/10/04 Invited speaker, National Center for Biodefense, George Mason University.  Physiology of chronic biotoxin illness.
  • 4/30/04 American Society for Microbiology, Integrating Metabolism and Genomics, Montreal, Quebec.  Linkage disequilibrium of HLA DR genotypes, autoantibodies and wingspan/height ratios in patients with environmentally acquired toxigenic illness
  • 5/25/04 104th General meeting of American Society for Microbiology, New Orleans, Louisiana.  Melanocyte Stimulating Hormone (MSH) Deficiency in Chronic Fatigue Syndrome Associated with Nasal Carriage of Coagulase Negative Staphylococci
  • 6/22-23 2004 Mealey’s National Mold Litigation Conference, Orlando, Florida.  Invited speaker, Emerging medical issues in mold illness.
  • 10/8/04 American (now International) Association for Chronic Fatigue Syndrome, Madison, Wisconsin.  Chronic Fatigue Syndrome:  Lessons from the Biotoxin Pathway
  • 12/4/04 Johns Hopkins University, Occupational and Environmental Medicine Conference, Chronic Illness from Water-Damaged Buildings:  Just Another Stop Along the Biotoxin Pathway
  • 12/9-10/04 Mealey’s Construction Defect and Mold Litigation Conference, Las Vegas, Nevada, Why the Institute of Medicine Report is Stale
  • 9/6-10/05 International Symposium on Cyanobacteria and Harmful Algal Blooms, US EPA Research Triangle Park, NC.  Characterization of chronic human illness associated with exposure to cyanobacterial harmful algal blooms predominated by Microcystis
  • 11/2/05 Mid-Shore Lyme Disease Association, Acute and chronic Lyme disease:  lessons from the Biotoxin Pathway.  Easton, Maryland.
  • 2/16/06 Drexel University School of Medicine, Philadelphia, Pa. Visiting professor series.  It’s a Long Way from Pocomoke
  • 3/4/06 CAM Expo East, NYC, NY.  Physiology of fibromyalgia and Chronic Fatigue Syndrome
  • 3/25/06 Mid-Shore Lyme Disease Association, Easton, Md.  Rise of the innates; Lyme disease 2006:lessons from a billion years ago
  • 4/1/06 Third Annual Mold Conference, Houston, Texas.  Mold Illness:  So What do We Really Know?
  • 5/6/06 American College for Advancement in Medicine, Dallas Texas. Lyme disease update:  Rise of the innates
  • 6/28/07 Quarterly Medical Director’s Conference; Department of Mental Health Services, State of Virginia, “Inflammatory central nervous system illness caused by environmental exposures presenting as psychiatric illness.”
  • 8/6/07 International CFS leaders conference, Sonoma County, California.  “Shoemaker for dummies.”
  • 12/6/07 National Toxicology Program NIEHS, RTP, NC.  Physiologic disturbances and causality in patients with illness acquired following exposure to water-damaged buildings
  • 4/12/08 Lyme and autism, LIA Foundation, “What biotoxins do to inflammation and brains.” Fort Lee, NJ
  • 6/2/08 AIHA continuing education program Round Table, Minneapolis; Steve Vesper, Greg Boothe, Gil Cormier, King teh Lin co-panelists. Integrating Field, Laboratory and Clinical data for the IAQ investigation. Comparison of indices of human health and building healthy:  SAIIE meets ERMI.
  • 6/15/08 7th International Conference on Neurotoxicology, San Jose, Costa Rica.  Human health effects of acute and chronic exposure to toxigenic cyanobacteria. EPICOH-NEUREOH.
  • 10/4/08 ICIM XLIX Congress, Pittsburgh, Pa.  When Hygeia meets Panacea.
  • 9/10/09 Orange, Virginia. After the zinnias, then come the spirochetes, dinos and molds
  • 9/23/09 Healthy Buildings IX. Syracuse, NY. Elements of the Biotoxin Pathway.
  • 2/1/10 American Society for Microbiology. MSH deficiency in CFS is associated with MARCoNS
  • 5/28/10 Copenhagen. The academic basis of CFS/ME: Objective physiologic measures provide biomarkers for confirmation of diagnosis and guide therapy.
  • 9/10/10 Keystone. Expansion of use of plasma TGF beta-: a new paradigm for inflammatory illness.
  • 10/23/2011 Gordon Medical. The academic basis for treatment of CIRS-WDB
  • 10/23/2011 Gordon Medical. Mold illness: the view from 30,000 feet
  • 10/23/2011 Gordon Medical. Protocols, differential diagnosis: How can I be sure?
  • 10/23/2011 Gordon Medical. Biotoxin Pathway.
  • 10/23/2011 Gordon Medical. Algorithms, protocols, finishing thoughts
  • 11/12/2011 Wise Traditions, Weston Foundation, Dallas Texas Price.  Mold Illness: the view from 30,000 feet.
  • 9/12/14 George Washington Univ. CIRS: From anomaly to paradigm
  • 9/26/14. CorTechs, San Diego. When CIRS meets NeuroQuant
  • 3/15/15 Australia. Getting started on a CIRS work-up.
  • 3/15/15/ Australia. CIRS: An acronym for now and the future.
  • 3/15/15 Australia. Chronic inflammatory response: Mold, Lyme and much more.
  • 3/15/15 Australia. Genomics report: Patient Q.
  • 3/15/15 Australia. Genomics and CIRS.
  • 3/15/15 Australia. Inflammation in Lyme disease only affects areas that receive blood flow.
  • 11/15 Phoenix SM. NQ III: Lyme and mold and now grey matter nuclear atrophy.
  • 11/15 Phoenix SM. Introducing CIRS
  • 11/15 Phoenix SM. Proteomics of diagnosis and treatment of CIRS
  • 5/20/16 Cleveland Clinic. MARCoNS protocol
  • 5/20/16 Cleveland Clinic. Low VO2 max: It isn’t just CFS, you know
  • 5/20/16 Cleveland Clinic. Pulmonary hypertension: the ever-present concern for CIRS caregivers
  • 5/20/16 Cleveland Clinic. Time to learn transcriptomics: SNPs don’t cut it.
  • 5/20/16 Cleveland Clinic. Diagnosis and treatment of CIRS-WDB in the era of NeuroQuant and genomics
  • 5/20/16 Cleveland Clinic. From lionfish to Loxosoceles: the rarer CIRS. The pathway still holds.
  • 5/20/16 Cleveland Clinic. When inflammation becomes chronic: Introducing CIRS
  • 5.20.16 Cleveland Clinic. Proteomics of CIRS.
  • 4/6/17 A4M, Fort Lauderdale Florida. How to read your transcriptomics report.
  • 4/6/17 A4M, Fort Lauderdale, Florida. Plasticity of multinuclear grey matter atrophy: Clues from treatment
  • 4/6/17 A4M, Fort Lauderdale, Florida. CIRS Diagnosis and treatment; Focus on water-damaged buildings.
  • 4/6/17 A4M, Fort Lauderdale, Florida. MARCoNS Monsters
  • 4/6/17 A4M, Fort Lauderdale, Florida. Multinuclear grey matter nuclear atrophy: Age or inflammation?
  • 4/6/17 A4M, Fort Lauderdale, Florida. To treat transcriptomics
  • 2/28/18. Standard Process symposium. From CIRS to new therapies.
  • 5/4/2018 SM at Salisbury, Md. Expanding correction of NQ to superior lateral ventricle.
  • 5/4/2018 SM at Salisbury. Transcriptomics explained.
  • 5/4/2018. SM at Salisbury, Md.  Case report: VIP affecting cardiac coronary risk factors.
  • 6/1/2017 Lyme cardiomyopathy
  • 6/1/2017 CIRS: diagnosis and treatment, Nutripath lectures, Melbourne, Australia
  • 12/3/2018 US Department of Health and Human Services, Innovations in Lyme, invited speaker: “With wonder and respect.”
  • 1/20/2019 SM Fort Lauderdale. NQ: now to superior lateral
  • 1/20/2019 SM Fort Lauderdale. The clinical experience with VIP: A multisite report
  • 1/20/2019 SM Fort Lauderdale. The clinical effects of air purification on transcriptomics of two patients: A case/control study
  • 3/9/19 A4M Houston. Reading a GENIE report
  • 3/9/19 A4M Houston. Treatment of NQ: from grey matter to superior lateral ventricle
  • 3/9/19 A4M Houston. It’s a long way from Pocomoke
  • 3/9/19 A4M Houston. Case definition of CIRS: Ancillary studies and labs



12/10/98               Georgetown Center for Food Policy, Washington, D.C.

1.    Pfiesteria; Diagnosis and Treatment

  1. Environmental Factors Contributing to Pfiesteria Blooms

6/15/99                 Maryland Academy of Family Practice Annual Meeting 

  1. Pfiesteria Human Illness Syndrome
  2. Use of Troglitazone in Treatment of Hyperinsulinemic Obesity

5/01/00                 Association of Research in Vision and Ophthalmology, Fort Lauderdale, Florida.

  1. Use of Contrast Sensitivity in Diagnosis of Chronic Neurotoxin-Mediated Illness

6/4/00                   US EPA National Health and Environmental Effects and Research Lab

                1.  Human Health and Environmental Indicators

 2.  Possible Estuarine Associated Syndrome, Diagnosis and Treatment

10/18/00               CDC National Pfiesteria Conference Stone Mountain, Georgia.  1. Evidence of Successful treatment of the chronic neurotoxin-mediated illness of Possible     Estuarine Associated Syndrome

2.    Possible Cylindrospermopsis Associated Human Illness Syndrome

 6/20/01                81st Meeting of Endocrine Society, Denver, Colorado

  1. Use of Rosiglitazone in Treatment of     Hyperinsulinemic Obesity (SmithKlineBeecham funded research)

 6/15/02                San Francisco, American Diabetes Association .  Use of Pioglitazone to Prevent Intensification of Persistent Symptoms following Cholestyramine Treatment of Patients with the Post-Lyme Syndrome (Takeda Pharmaceuticals North America, funded research)

11/15/02              Denver, Colorado, ASTMH. Differential Association of HLA DR by PCR Genotypes with  Susceptibility to Chronic, Neurotoxin-Mediated Illnesses

9/10-9/12/03       Saratoga Springs, NY 5th International Conference on Bioaerosols, Fungi, Bacteria, Mycotoxins and Human Health.  Sick Building Syndrome, diagnosis and treatment of a biotoxin associated illness with multiple biomarkers:  prospective confirmation of causation in 156 patients from 150 buildings using 11 different biomarkers

10/8/04                 American Association for Chronic Fatigue Syndrome, Madison, Wisconsin

  1. Chronic Fatigue Syndrome:  Lessons from the Biotoxin Pathway;

12/21/09               Advances Against Aspergillus Conference, 2/6/10; Rome, Italy.  Occupational sphenoid mycetoma with Aspergillus terreus (4.4 X 6.3 cm) resolved with intranasal cyclosporine/voriconazole therapy.  Gray, M, Hooper D, Maluf G, Dumanov  J, Shoemaker R.

10/22/10               GTCbio 4th Annual Biomarker and Development Conference, San Francisco, Calif.  The expansion of clinical use of plasma TGF beta-1: the new paradigm for chronic inflammatory illness.  Shoemaker R, Bronfin B, Tilton R, Rundell C. Hoey J.

3/13/2013            7th International Conference: Safe and Effective Flood and Mold Remediation-after Super Storm Sandy and other Natural Disasters, Galloway, NJ.  Neuropsychiatric symptoms in patients with illness acquired following exposure to WDB are associated with structural abnormalities: a volumetric MRI study using NeuroQuant.


Physician Education Seminars

4/8/2011; 4/9/2011, 9/15/2-15  Hopkinton, Massachusetts   Biotoxins, inflammation and chronic illnesses

10/26, 27/2011; Santa Rosa California Gordon Medical Associates

11/11-15/15 State of the Art Cutting Edge second annual conference, Phoenix (3 lectures)

4/15-17/2016 Surviving Mold Virtual Conference, Fort Worth, Texas.  7 lectures.

5/18, 5/19/2016.  CME lectures at the Cleveland Clinic, Ohio.



Congressional testimony:  House of Representatives 9/22/04 staff briefing and press conference Member John Conyers; Health effects of exposure to water-damaged buildings

US Senate HEAL committee 1/12/06, Human health effects of mold exposure, Senator Edward Kennedy.

Maryland Senate testimony:  Commentary on indoor air quality task force; Senator Rob Garagiola 3/29/06


IRB Studies

  1. SmithKline Beecham 9/99    IRB: Quorum  

Use of rosiglitazone in treatment of hyperinsulinemic obesity.

  1. Glaxo Wellcome 10/00    IRB: Copernicus Group

Use of Mepron (atovaquone) in patients with Borrelia burgdorferi coinfected with Babesia microti refractory to antibiotics and cholestyramine.

  1. Protocol IND 63,993 Use of Melanocyte Stimulating Hormone in Patients with Chronic Fatigue
  2. Protocol SBS 51326 Use of visual contrast sensitivity testing and cholestyramine therapy in diagnosis and treatment of environmentally-acquired, chronic, neurotoxin-mediated illness from indoor exposure  IRB Copernicus 7/23/02 
  3. SPL-CFS 123 Treatment of Chronic Fatigue Syndrome in patients with nasal colonization of multiply antibiotic resistant, biofilm-forming species of coagulase negative Staph using nasal instillation of diluted Staphage Lysate® IRB Copernicus 11/27/03
  4. Retrospective use of laboratory results in a report of group results:  Complement split products C3a, C4a, MMP9 and visual contrast sensitivity are markers for acute acquisition of Lyme disease. IRB Copernicus Group, 9/8/05
  5. Retrospective use of individual laboratory results in a report of group results:  Defining Sick Building Syndrome in adults and children as a biotoxin-associated illness.  IRB Copernicus Group 10/20/05
  6. Retrospective use of individual laboratory results in a report of group results:  Eight-year follow-up of Possible Estuarine Associated Syndrome cases and controls.  IRB Copernicus Group 11/7/05
  7. Erythropoietin lowers C4a, corrects refractory symptoms and normalizes selected abnormal brain chemistry in patients with illness acquired following exposure to water-damaged buildings.  IRB Copernicus Group CFS 50-2006 10/18/06.
  8. Retrospective use of individual medical parameters in a case/control study:  Baseline symptoms, visual contrast sensitivity and laboratory results in cases of chronic ciguatera compared to controls.  10/19/09.
  9. Vasoactive intestinal polypeptide lowers C4a and TGFbeta-1, corrects refractory symptoms and normalizes selected abnormal biomarkers in patients with Chronic Fatiguing Illnesses (CFI) who have chronic inflammatory response syndromes 12/21/09.
  10. Retrospective calculation of chemical parameters identified by magnetic resonance spectroscopy I four areas of the brain before and after erythropoietin therapy. 6/14/10.
  11. Retrospective use of individual medical parameters in a case/control study: Baseline symptoms, proteomic measures and genomics compared to controls. 3/15/2013.
  12. Retrospective use of volumetric central nervous system parameters in a case/control study: baseline findings using NeuroQuant  ® compared to controls 2/1/2014                             


Lecturer   Medical Mutual Insurance Company 2/00   Risk Management in Primary Care



  • American Academy of Family Practice, Finalist, National Family Practice Physician of the Year, 2002
  • Maryland Family Practice Doctor of the Year 2000, MAFP
  • Maryland Governor’s Volunteer of the Year for the Environment, 4/97
  • Local Governor’s Advisory Committee for Innovation and Restoration of Chesapeake Bay 1994
  • State of Maryland Bill Jones Environmental Award 1995
  • Maryland Dept. Agriculture Conservator of the Year 1994
  • Good Neighbor Award 1993
  • Dr. Henry P. and M. Page Laughlin Award for Distinguished Authorship/Editorial Award 5/98
    • (Maryland Medical Journal)


Commencement Speaker

  • Malcolm Grow Medical Center (Andrews AFB 6/98)


CME Speaker

  • Audio Digest Vol. 47 No. 22 6/99 Washington D.C.
  • Audio Digest Vol. 48 No. 14 12/99 Washington D.C.


Issued patent 9/26/2017 (9, 770, 170 B2)  : Methods for diagnosing, treating and monitoring Chronic Inflammatory Response Syndrome. 8/6/2012

Completed patent application above 8/3/2013


Health Investigations and treatment, cohorts of patients exposed to toxigenic fungi (> 4 patients)


  • Norfolk Naval Base Housing group 12/2011-1/28/2013 60 patients
  • Lanier Middle School Fairfax, Virginia 10/09 26 patients
  • Port Richey, Florida.  4/09 16 patients
  • Wabash Valley Surgical Center, Terre Haute, Indiana.  2/08.  9 patients.
  • FAA Air Traffic controllers, Metro Tower, Detroit, Michigan.  7/07. 17 patients
  • Glenwood Springs, Colorado.  Robert Cordova, leader of cohort. 7/28/06 14 patients.
  • Fraternal Order of Police; Queen Anne’s County, Maryland 5/06 8 patients
  • St. Bernard Parish, Louisiana, on the Scotia Prince 2/06; with Richard Lipsey, PhD; firefighters, homeless adults and children, Parish employees, ship’s crew and health care workers.  212 patients.
  • Residences at the Ritz; Ritz Carlton 1155 and 1111 23rd St NW Washington DC 10 patients
  • Newmarket Courthouse, Toronto, Ontario, Canada. 12/04-present; 300 employees at risk
  • International Marine Terminal, Portland, Maine. 11/05. 16 patients.  
  • Topsail (NC) School District. 9/04. 260 patients.
  • Prince Georges County Fraternal Order of Police; Oxon Hill, Md. 6/03. 52 patients.
  • Hampton Bays United Free Elementary School, Long Island, NY.  5/03. 44 patients.
  • State Iowa Dept Corrections, Davenport, Iowa. 1/03. 10 patients.
  • Baltimore-Washington Conference United Methodist Church, Columbia, Md. 12/02.  55 patients
  • Eastern Correctional Institution, Westover, Md. 5/02. 11 patients
  • Accomack County (Virginia) Social Services Building. 4/02. 11 patients.
  • Multi-Services Building 201 Baptist St., Salisbury, Md.  4/02. 20 patients.
  • Police Department Berlin, Md. 4/02.  5 patients.
  • Somerset County Library, Princess Anne, Md. 2/02. 13 patients.
  • Somerset County Circuit Court, Princess Anne, Md.  10/01. 5 patients.
  • Somerset County District Court, Princess Anne, Md.  6/01. 12 patients.
  • Worcester County Board of Education Newark, Md. 5/99. 8 patients.
  • Wicomico County Sheriffs Department, Salisbury, Md. 2/99. 25 patients.